Biblio Discovery — Demo Discovery Service

3 hasil untuk "Mark Lin"

Menampilkan 1–3 · 2,24 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

    Caicun Zhou; Suresh S. Ramalingam; Tae Min Kim dkk.

    JAMA Oncology · 2021 · Inggris · OpenAlex Scopus

    IMPORTANCE: Metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral tyrosine kinase inhibitor designed to selectively target EGFRex20ins mutations. OBJECTIVE: To evaluate treatment outcomes and…

  2. Artikel Jurnal

    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first…

  3. Artikel Jurnal Teks lengkap

    Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim…